molecules of the month

“compound 3d”

sphingosine-1-phosphate recep. mod. prodrug

for multiple sclerosis, proj. human t1/2 of 5d

from opt. of prior S1P1 modulators

ACS Med. Chem. Lett., Aug. 11, 2020

Bristol-Myers Squibb, Princeton, NJ

Chemical structure of the "compound 3d" prodrug
1 min read

“compound 3d” is a prodrug which is phosphorylated in vivo to form a potent sphingosine-1-phopshate receptor modulator. BMS took two previous compounds into the clinic for MS with the goal of differentiating from fingolimod on safety. One potential issue for a previous compound was an overly long (12 day) half-life which could be undesirable in certain settings such as those involving drug-drug interactions. Therefore “compound 3d” was developed to have a shorter preducted human half-life of “only” 5 days.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: